💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Somatrogon

CHEMBL4297830 Phase 4 معتمد Protein
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Somatrogon is a long-acting recombinant human growth hormone-CTP (carboxy-terminal peptide) fusion protein for once-weekly treatment of pediatric growth hormone deficiency, created by fusing human GH with three CTP sequences from human chorionic gonadotropin beta-subunit. The CTP extensions reduce renal clearance and extend the half-life, enabling less frequent dosing while maintaining full GH receptor agonist activity. It provides equivalent growth-promoting effects to daily GH therapy with improved convenience.

آلية العمل

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

Somatrogon is a long-acting recombinant human growth hormone-CTP (carboxy-terminal peptide) fusion protein for once-weekly treatment of pediatric growth hormone deficiency, created by fusing human GH with three CTP sequences from human chorionic gonadotropin beta-subunit. The CTP extensions reduce renal clearance and extend the half-life, enabling less frequent dosing while maintaining full GH receptor agonist activity. It provides equivalent growth-promoting effects to daily GH therapy with improved convenience.

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Yes, Somatrogon is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297830. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.